Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Director departure
Employment agrmnt
SAVIENT PHARMACEUTICALS INC (SVNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/20/2019 CT ORDER Form CT ORDER - Confidential treatment order:
05/23/2017 CT ORDER Form CT ORDER - Confidential treatment order
05/30/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of May 1, 2014 through May 31, 2014"
05/20/2014 8-K Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Financial Stateme...
Docs: "Confirmation Order of the United States Bankruptcy Court for the District of Delaware",
"Monthly Operating Report for the Period of April 1, 2014 through April 30, 2014"
04/17/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of March 1, 2014 through March 31, 2014"
03/20/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of February 1, 2014 through February 28, 2014"
03/18/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Disclosure Statement with Respect to Proposed Plan of Liquidation of Savient Pharmaceuticals, Inc., et al.",
"Proposed Plan of Liquidation of Savient Pharmaceuticals, Inc., et al."
02/20/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of January 1, 2014 through January 31, 2014"
02/14/2014 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/11/2014 SC 13G/A FRANKLIN RESOURCES INC reports a 0% stake in SAVIENT PHARMACEUTICALS, INC.
02/11/2014 SC 13G/A VANGUARD GROUP INC reports a 0% stake in Savient Pharmaceuticals Inc
02/11/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Proposed Plan of Liquidation of Savient Pharmaceuticals, Inc., et al.",
"Proposed Disclosure Statement with Respect to Proposed Plan of Liquidation of Savient Pharmaceuticals, Inc., et al."
01/22/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of December 1, 2013 through December 31, 2013"
01/10/2014 8-K Resignation/termination of a director
Docs: "Amendment to the By-Laws of Savient Pharmaceuticals, Inc., effective January 8, 2014"
01/07/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Certification of Counsel Regarding Final Cash Collateral Order and Budget"
12/31/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Notice of Current Working Draft of Cash Collateral Budget and Illustrative Sources and Uses"
12/20/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of November 1, 2013 through November 30, 2013"
12/13/2013 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Acquisition Agreement, by and among Savient Pharmaceuticals, Inc., Savient Pharma Holdings, Inc. and Crealta Pharmaceuticals LLC (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"Sale Order, granting the Debtors' motion to sell substantially all of its assets"
12/05/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period of October 15, 2013 through October 31, 2013"
11/21/2013 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/14/2013 10-Q Quarterly Report for the period ended September 30, 2013
11/12/2013 SC 13G/A Palo Alto Investors, LLC reports a 0% stake in Savient Pharmaceuticals, Inc.
11/06/2013 8-K Quarterly results
10/30/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Initial Monthly Operating Report"
10/15/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Incentive Agreement"
10/15/2013 8-K Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direc...
Docs: "Acquisition Agreement, by and among Savient Pharmaceuticals, Inc., Savient Pharma Holdings, Inc., US WorldMeds, LLC and Sloan Holdings C.V. (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"SAVIENT PHARMACEUTICALS COMMENCES VOLUNTARY CHAPTER 11 PROCEEDING; SEEKS TO CONDUCT AUCTION AND SALE UNDER SECTION 363"
08/14/2013 10-Q Quarterly Report for the period ended June 30, 2013
08/14/2013 8-K Quarterly results
Docs: "Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results"
07/25/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE is made and entered into by and between Louis Ferrari and Savient Pharmaceuticals, Inc. . RECITALS WHEREAS, Savient has employed you since February 21, 2011 pursuant to an Employment Agreement previously entered into by the Parties, originally as of February 7, 2011 and as amended and restated as of July 9, 2012, a copy of which is attached hereto as “ Exhibit A ” ; and WHEREAS, consistent with Savient's obligations under the Employment Agreement, on June 19, 2013 , the Company provided you with sixty days' advance written notice of the termination of your employment pursuant to Section 7.4 of the Employment Agreement ; and WHEREAS, you have been relieved from your duties as Pre..."
06/20/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Savient Pharmaceuticals Announces Formation of Office of the President"
06/10/2013 SC 13G/A Capital Research Global Investors reports a 0% stake in Savient Pharmaceuticals, Inc.
06/04/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/15/2013 10-Q Quarterly Report for the period ended March 31, 2013
04/29/2013 DEF 14A Form DEF 14A - Other definitive proxy statements
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy